Citalopram updated on 07-01-2025

Intrauterine deaths (as a whole or unspecified)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7943
R24026		 Sjaarda (Citalopram/Escitalopram), 2020 Pregnancy loss (any loss occurring after hCG detection of pregnancy) early pregnancy prospective cohort unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 0.96 [0.52;1.76] 7/37   143/662 150 37
ref
S7179
R20217		 Colvin, 2011 Terminations of Pregnancy (both spontaneous abortions and elective) 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.21 [0.84;1.41] 239/1,012   24,313/119,840 24,552 1,012
ref
Total 2 studies 1.17 [0.92;1.48] 24,702 1,049
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Sjaarda (Citalopram/Escitalopram), 2020Sjaarda, 2020 1 0.96[0.52; 1.76]1503715%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Colvin, 2011Colvin, 2011 1.21[0.84; 1.41]24,5521,01285%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: unclearROB mesure: moderateROB reporting: moderate Total (2 studies) I2 = 0% 1.17[0.92; 1.48]24,7021,0490.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Citalopram/Escitalopram;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.17[0.92; 1.48]24,7021,0490%NASjaarda (Citalopram/Escitalopram), 2020 Colvin, 2011 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.17[0.92; 1.48]24,7021,0490%NASjaarda (Citalopram/Escitalopram), 2020 Colvin, 2011 2 Tags Adjustment   - No  - No 1.21[0.93; 1.57]24,5521,012 -NAColvin, 2011 1   - Yes  - Yes 0.96[0.52; 1.77]15037 -NASjaarda (Citalopram/Escitalopram), 2020 1 Monotherapy   - no or not specified  - no or not specified 0.96[0.52; 1.77]15037 -NASjaarda (Citalopram/Escitalopram), 2020 1   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.21[0.93; 1.57]24,5521,012 -NAColvin, 2011 1 All studiesAll studies 1.17[0.92; 1.48]24,7021,0490%NASjaarda (Citalopram/Escitalopram), 2020 Colvin, 2011 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.17[0.92; 1.48]24,7021,0490%NASjaarda (Citalopram/Escitalopram), 2020 Colvin, 2011 20.510.01.0